Loading...
Loading...
RVMD| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 175.7M |
| Operating I/L | -175.7M |
| Other Income/Expense | 19.4M |
| Interest Income | 20.4M |
| Pretax | -156.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -156.3M |
Revolution Medicines, Inc. is a clinical-stage precision oncology company specializing in developing therapies to target RAS-addicted cancers. Their product pipeline includes RMC-4630, an SHP2 inhibitor in Phase 1/2 clinical trial for solid tumors, RMC-5845, a selective SOS1 inhibitor, RMC-5552, a hyperactivated mTORC1 signaling inhibitor, and RMC-6291 and RMC-6236, mutant-selective and RAS-selective inhibitors respectively. They also develop RAS(ON) Inhibitors targeting specific RAS variants. The company generates revenue through the research, development, and potential commercialization of these precision oncology therapies.
